Clinical Trial: JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714304) titled 'JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC' on July 15.

Brief Summary: This is a single-arm clinical study evaluating the safety, tolerability, and preliminary efficacy of JS212 in combination with JS111 as first-line treatment in participants with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy for advanced disease.

The study consists of a safety lead-in stage followed by a clinical expansion stage. Approximately 20 participants are planned to be enrolled across the two stages. Pa...